Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06764771 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
A Phase 1 study of Advanced Malignant Tumors, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 1
- Development phase
- 437
- Enrollment target
- 7
- Study locations
NCT06764771 is a Phase 1 study of Advanced Malignant Tumors that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 437 participants. The trial reports 7 study locations across 6 states.
The verdict
NCT06764771, a Phase 1 study of Advanced Malignant Tumors, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 437 participants
- Enrollment target
- 7
- Study locations
Study Summary
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Cetuximab
- DRUG Adagrasib
- DRUG BMS-986488
Study Locations (7)
Quebec
- Local Institution - 0015 - Montreal
- Local Institution - 0016 - Québec
New Jersey
- Local Institution - 0021 - Hackensack
Pennsylvania
- Local Institution - 0020 - Allentown
Tennessee
- Local Institution - 0024 - Germantown
Queensland
- Local Institution - 0031 - Brisbane
British Columbia
- Local Institution - 0032 - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 437 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2027-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06764771
The ClinicalTrials.gov registry entry for NCT06764771 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 437 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Malignant Tumors appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT06764771 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Quebec, New Jersey, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06764771 about?
NCT06764771 is a clinical study titled "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors". This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
What is the current status of trial NCT06764771?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 437 participants. The study started on 2025-03-25. Estimated completion is 2027-10-15.
What conditions does trial NCT06764771 study?
This clinical trial studies the following conditions: Advanced Malignant Tumors.
What interventions are being tested in trial NCT06764771?
The interventions under investigation include: Nivolumab (DRUG), Cetuximab (DRUG), Adagrasib (DRUG), BMS-986488 (DRUG).
Who is sponsoring clinical trial NCT06764771?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06764771 being conducted?
This trial has 7 study locations across New Jersey, Pennsylvania, Tennessee, Queensland, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.